FDA Should Focus on Helping Companies With Vaccines, Jim Cramer Says

Katherine Ross

The F.D.A., a day after issuing an emergency OK to Roche's antibody test, said in a statement that it was stepping up its scrutiny of antibody tests.

"High-quality antibody tests (a type of serological test) can help us understand a person’s and population’s exposure to COVID-19. A person who has been exposed to, and recovered from, COVID-19 will likely have antibodies to the SARS-CoV-2 virus in their blood. These tests may be important for guiding our next steps in the fight against this pandemic, such as by providing information on disease prevalence and the frequency of asymptomatic infection, and also by identifying potential donors of “convalescent plasma,” an approach in which blood plasma containing antibodies from a recovered individual serves as a therapy for an infected patient with severe or immediately life-threatening disease," explained the F.D.A. in a statement.

“We, unfortunately, see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans’ anxiety,” they continued. “Some test developers have falsely claimed their serology tests are F.D.A. approved or authorized. Others have falsely claimed that their tests can diagnose Covid-19 or that they are for at-home testing.”

Watch the full video above for Jim Cramer's full take.

Want to know what Cramer and his team at Action Alerts PLUS are thinking about the markets and the stocks they're watching? Sign up on Action Alerts PLUS for more.

Cramer and the team are weighing in on what members need to know about the coronavirus pandemic's impact on the market. Here's how you can recap his entire April show.

Watch More of the Latest Videos on TheStreet and Jim Cramer

LIVE WITH JIM CRAMER - WATCH THE REPLAY
Enter your email to register or login. Registration information may be shared with advertising partners in accordance with our Privacy Policy.